Response to: Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: The real challenge? Correspondence

   

Authors:	Vogel, A.; Zhen, H.; Veronese, M. L.; Abou-Alfa, G. K.
Title:	Response to: Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: The real challenge?
Keywords:	treatment response; overall survival; cancer patient; follow up; letter; progression free survival; risk factor; gene rearrangement; gene fusion; bile duct carcinoma; fibroblast growth factor receptor 2; overall response rate; human; pemigatinib
Journal Title:	ESMO Open
Volume:	9
Issue:	11
ISSN:	2059-7029
Publisher:	European Society for Medical Oncology
Date Published:	2024-11-01
Start Page:	103937
Language:	English
DOI:	10.1016/j.esmoop.2024.103937
PROVIDER:	scopus
PMCID:	PMC11513512
PUBMED:	39423455
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85206323726&doi=10.1016%2fj.esmoop.2024.103937&partnerID=40&md5=59e207f3e4190e74368b6e385f669da8
Notes:	Letter -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/219836